吉林敖東(000623.SZ):積極探索通過AI技術優化藥物篩選、臨牀試驗設計等環節的可能性
格隆匯3月19日丨吉林敖東(000623.SZ)在投資者互動平台表示,公司始終密切關注醫療健康產業的技術變革與市場趨勢,對AI技術在醫藥研發、生產管理及大健康領域的應用前景保持高度關注。當前,公司已在醫藥全流程管理中引入信息化、數字化、智能化技術,通過智能工廠建設實現設備互聯、數據互通與柔性製造,為未來進一步探索AI賦能奠定基礎。在研發端,公司持續開展中藥經典名方、配方顆粒及創新藥研究,並積極探索通過AI技術優化藥物篩選、臨牀試驗設計等環節的可能性,以提升研發效率與精準度。在產業升級方面,公司致力於通過智能製造模式推動生產流程的高效化與質量控制的精細化,這與AI技術驅動的醫藥工業變革方向高度契合。未來,公司將結合行業動態與技術成熟度,審慎評估AI技術與醫藥主業、大健康業務的融合可能性,持續以科技創新為引擎,推動高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.